Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
JW (Cayman) Therapeutics HK$2.33 billion Hong Kong IPO
Davis Polk advised the underwriters in the initial public offering of JW (Cayman) Therapeutics Co. Ltd on the Hong Kong…
Atea Pharmaceuticals $345 million IPO
Davis Polk advised the representatives of the underwriters in connection with the $345 million initial public offering of 14…
Coloplast acquisition of Nine Continents Medical
Davis Polk advised Coloplast on its acquisition of Nine Continents Medical, an early stage company pioneering an implantable…
Allakos $272 million follow-on offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the…
Biodesix $72 million IPO
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $72 million…
MultiPlan $1.3 billion senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A/Regulation S offering by MPH…
Turning Point Therapeutics $460 million stock offering
Davis Polk advised the joint book-running managers in connection with a $460 million SEC-registered common stock…
Abcam $180 million U.S. IPO of ADSs
Davis Polk advised the representatives of the several underwriters in connection with Abcam plc’s $180 million U.S…
Xspray Pharma SEK 265 million private placing of new shares
Davis Polk advised Xspray Pharma AB (publ) on a private placing of new shares. The private placing raised gross proceeds of…
Aligos Therapeutics $150 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $150 million initial public…